Abzena PLC Issue of Equity (9019U)
24 January 2017 - 6:00PM
UK Regulatory
TIDMABZA
RNS Number : 9019U
Abzena PLC
24 January 2017
Abzena plc
Issue of Ordinary shares
Cambridge, UK, 24 January 2017 - Abzena plc (AIM: ABZA, 'Abzena'
or the 'Company'), the life sciences group providing services and
technologies to enable the development and manufacture of
biopharmaceutical products, announces that pursuant to the
successful completion of the initial vesting period of the
restricted stock units issued to employees on the acquisition of
The Chemical Research Solution LLC (known as 'TCRS') in December
2015, an application has been made to the London Stock Exchange for
the admission of 715,772 new ordinary shares of GBP0.002 each ('New
Ordinary Shares') to trading on AIM. Admission of the New Ordinary
Shares is expected to take place at 8:00am on 27 January 2017.
The New Ordinary Shares rank pari passu with the Company's
existing issued ordinary shares.
Following admission of the New Ordinary Shares to AIM, the
Company's enlarged issued share capital will comprise 137,846,327
ordinary shares of GBP0.002 each with voting rights. No shares of
the Company are held in treasury. The total number of voting rights
in the Company is therefore 137,846,327. The figure of 137,846,327
ordinary shares may be used by shareholders in the Company as the
denominator for the calculations by which they will determine if
they are required to notify their interest in, or a change in their
interest in, the share capital of the Company under the Financial
Conduct Authority's Disclosure Guidance and Transparency Rules.
-Ends-
Enquiries:
Abzena plc
John Burt, Chief Executive
Officer Julian Smith, Chief
Financial Officer +44 1223 903498
Numis (Nominated Adviser and
Broker)
Clare Terlouw / James Black +44 20 7260
/ Paul Gillam 1000
N+1 Singer (Joint Broker) +44 20 7496
Aubrey Powell / Liz Yong 3000
Instinctif Partners +44 20 7457
Melanie Toyne Sewell / Rozi 2020
Morris abzena@instinctif.com
Notes to Editors
About Abzena
Abzena (AIM: ABZA) provides proprietary technologies and
complementary services to enable the development and manufacture of
biopharmaceutical products, a growing area that requires specialist
knowledge and expertise. The Group has a global customer base which
includes the majority of the top 20 biopharmaceutical companies as
well as large and small biotech companies and academic groups.
The term "Abzena inside" is used by Abzena to describe products
that have been created using its proprietary technologies and are
being developed by its partners, and include Composite Human
Antibodies(TM) and ThioBridge(TM) Antibody Drug Conjugates (ADCs).
Abzena has the potential to earn future licence fees, milestone
payments and/or royalties on "Abzena inside" products.
Abzena offers the following services and technologies across its
principal sites in Cambridge (UK), San Diego, California (USA) and
Bristol, Pennsylvania (USA).
-- Immunogenicity assessment, protein engineering to create
humanized antibodies and deimmunised therapeutic proteins, and cell
line development for manufacture.
-- Contract process development and manufacture of
biopharmaceuticals, including monoclonal antibodies, recombinant
proteins, vaccines, and gene therapy and cell therapy products, for
preclinical and clinical studies.
-- Proprietary site-specific conjugation technologies for
antibody drug conjugate development and solutions for optimizing
the therapeutic properties of biopharmaceuticals.
-- Contract chemistry and bioconjugation business focused on
ADCs and is establishing the capability to manufacture ADCs to GMP
standards.
For more information, please see www.abzena.com
This information is provided by RNS
The company news service from the London Stock Exchange
END
IOEFXLLLDFFEBBL
(END) Dow Jones Newswires
January 24, 2017 02:00 ET (07:00 GMT)
Abzena (LSE:ABZA)
Historical Stock Chart
From Apr 2024 to May 2024
Abzena (LSE:ABZA)
Historical Stock Chart
From May 2023 to May 2024